Nation
World
Business
Politics
Opinion
Sports
Crime
Science
Tech
Health
Entertainment
Life
Oddities

BioNTech SE ADR underperforms Tuesday when compared to competitors

Por: MarketWatch Business January 13, 2021

thumbnail

The ADR underperformed when compared to some of its competitors Tuesday, as AbbVie Inc. rose 0.70% to $109.78 and Amgen Inc. fell 0.41% to $236.59. Trading volume (3.6 M) remained 941,464 below its 50-day average volume of 4.5 M. Editor's Note: This story was auto-generated by using data from Dow Jones and FactSet.... + full article



Similar News

Pfizer, BioNTech boost vaccine output goal by more than 50%

The Boston Globe USA Business January 11, 2021

thumbnail(Bloomberg)— Pfizer and BioNTech plan to produce 2 billion doses of their COVID-19 vaccine this year, boosting previously expected output by more than 50 percent in response to surging global demand.The companies have already agreed to deliver more than 1 billion doses in... + más

Here are 5 things to know about BioNTech and the married couple behind the COVID-19 vaccine with Pfizer | MarketWatch

FDA advisers give thumbs up to Pfizer vaccine, paving way for authorization | Ars Technica


Tesla Inc. stock underperforms Tuesday when compared to competitors despite daily gains

MarketWatch USA Business December 29, 2020

thumbnailThe stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Toyota Motor Corp. ADR rose 0.48% to $153.34, General Motors Co. fell 0.22% to $41.57, and Honda Motor Co. Ltd. ADR fell 0.63% to $28.22. Trading volume (22.5 M) remained 21.1 million... + más

Watch Out, Tesla. Ford’s Electric Mustang Could Be a Threat. | MarketWatch

Tesla Is Joining the S&P 500. This Stock Is Coming Out. | MarketWatch


BioNTech SE ADR underperforms Tuesday when compared to competitors despite daily gains

MarketWatch USA Business December 29, 2020

thumbnailThe ADR underperformed when compared to some of its competitors Tuesday, as AbbVie Inc. rose 1.21% to $104.70 and Amgen Inc. rose 1.44% to $226.87. Trading volume (3.3 M) remained 1.0 million below its 50-day average volume of 4.3 M. Editor's Note: This story was... + más

Capital gains are the profits you make from selling your investments, and they can be taxed at lower rates | Business Insider

Tesla Inc. stock underperforms Tuesday when compared to competitors despite daily gains | MarketWatch


Tesla Inc. stock underperforms Monday when compared to competitors

MarketWatch USA Business December 22, 2020

thumbnailThe stock underperformed when compared to some of its competitors Monday, as Toyota Motor Corp. ADR fell 1.30% to $151.77, General Motors Co. rose 0.49% to $41.21, and Honda Motor Co. Ltd. ADR fell 2.52% to $29.00. Trading volume (56.6 M) eclipsed its 50-day average volume of... + más

Tesla Is Joining the S&P 500. This Stock Is Coming Out. | MarketWatch

Tesla Is Joining the S&P 500. This Stock Is Coming Out. | MarketWatch


AstraZeneca PLC ADR underperforms Thursday when compared to competitors

MarketWatch USA Business December 17, 2020

thumbnailThe ADR underperformed when compared to some of its competitors Thursday, as AbbVie Inc. rose 0.24% to $104.89, Amgen Inc. rose 1.23% to $231.24, and Gilead Sciences Inc. rose 0.22% to $59.07. Trading volume (13.9 M) eclipsed its 50-day average volume of 7.4 M. Editor's... + más

AstraZeneca's COVID-19 Vaccine Authorized In UK | RTT News

AstraZeneca stock tumbles as Alexion shares soar after companies agree on takeover deal | MarketWatch


Tesla Inc. stock underperforms Wednesday when compared to competitors

MarketWatch USA Business December 16, 2020

thumbnailThe stock underperformed when compared to some of its competitors Wednesday, as Toyota Motor Corp. ADR rose 1.47% to $155.09, General Motors Co. fell 0.58% to $41.42, and Honda Motor Co. Ltd. ADR fell 0.64% to $29.46. Trading volume (41.5 M) eclipsed its 50-day average volume of... + más

Tesla Is Joining the S&P 500. This Stock Is Coming Out. | MarketWatch

Tesla Is Joining the S&P 500. This Stock Is Coming Out. | MarketWatch


Here are 5 things to know about BioNTech and the married couple behind the COVID-19 vaccine with Pfizer

MarketWatch USA Politics December 04, 2020

Shares in BioNTech have soared more than 257% year-to-date . Its vaccine candidate, developed in partnership with U.S. drugmaker Pfizer , was granted emergency-use on Wednesday, the first country to give approval. The rollout is set to begin next week, with people over the age... + más

First COVID-19 vaccine receives emergency-use authorization from U.S. FDA | MarketWatch

The timeline for vaccine approval around the world, as U.K. authorizes COVID-19 shot | MarketWatch



About iurex | Privacy Policy | Descargo de Responsabilidad |